Imaging tumor angiogenesis using 18F-Fluciclatide PET/CT in patients with colorectal and pancreatic cancer. - 18F-Fluciclatide tumor imaging

eiden University Medical Center0 个研究点目标入组 20 人开始时间: 2019年5月9日最近更新: 2019年11月25日

试验速览

暂无简介。

•Biopsy proven primary colorectal adenocarcinoma or suspected pancreatic ductal adenocarcinoma, as agreed on by multidisciplinary team;
•No prior chemo(radio)therapy in rectal cancer patients.
•Patients treated in the LUMC.
•Before patient registration, written informed consent must be given according to ICH/GCP, and national/local regulations.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Contraindication for PET (pregnancy, breast-feeding and severe claustrophobia);
•Impaired renal function (creatinine clearance < 60 mL/min according to the Cockcroft-Gault equation or ureum < 2x ULN (Upper limit of normal);
•Impaired liver function (ALAT, ASAT > 3 ULN or total bilirubin >2x ULN);
•Known allergy to pABA (p-aminobenzoate sodium salt);
•Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
•Inability to tolerate lying supine for the duration of a PET/CT examination (~30min).

发起方

eiden University Medical Center